Published in Pharma Law Weekly, September 26th, 2006
"NPC is multifactorial, and the genetic background may be a crucial etiologic factor. CCND1 is a key regulator of the cell cycle, and its altered activity is associated with the development of cancer. We analyzed the A870G CCND1 polymorphism by polymerase chain reaction/restriction fragment length polymorphism (PCR-RFLP) in 281 individuals, including 94 patients with NPC and 187 healthy individuals,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly